Qiagen Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
5,700
- Stock Symbol
-
QGEN
- Investments
-
62
- Share Price
-
$49.63
- (As of Thursday Closing)
Qiagen General Information
Description
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Contact Information
Website
www.qiagen.comCorporate Office
- Qiagen Strasse 1
- 40724 Hilden
- Germany
Corporate Office
- Qiagen Strasse 1
- 40724 Hilden
- Germany
Qiagen Stock Performance
As of 19-Nov-2026, Qiagen’s stock price is $49.63. Its current market cap is $10.2B with 206M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $49.63 | $49.56 | $32.53 - $57.81 | $10.2B | 206M | 3.66M | $1.87 |
Qiagen Financials Summary
As of 30-Sep-2026, Qiagen has a trailing 12-month revenue of $2.12B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 9,886,343 | 10,188,562 | 10,336,581 | 10,377,145 |
| Revenue | 2,115,649 | 2,089,999 | 1,978,214 | 1,965,311 |
| EBITDA | 654,681 | 652,947 | 300,240 | 609,563 |
| Net Income | 384,932 | 424,880 | 83,591 | 341,303 |
| Total Assets | 5,942,470 | 6,281,232 | 5,689,622 | 6,115,190 |
| Total Debt | 1,642,855 | 1,812,372 | 1,512,541 | 1,532,062 |
Qiagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Qiagen Comparisons
Industry
Financing
Details
Qiagen Competitors (13)
One of Qiagen’s 13 competitors is Standard BioTools, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Standard BioTools | Formerly VC-backed | Boston, MA | ||||
| HTG Molecular Diagnostics | Formerly VC-backed | Tucson, AZ | ||||
| Abcam | Corporate Backed or Acquired | Cambridge, United Kingdom | ||||
| Oxford Nanopore Technologies | Formerly VC-backed | Oxford, United Kingdom | ||||
| Illumina | Formerly VC-backed | San Diego, CA |
Qiagen Patents
Qiagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233823-A1 | Compositions and methods for pcr-based analysis of methylatable nucleic acids | Pending | 06-May-2025 | ||
| WO-2026229325-A1 | Microfluidic device and method for preparing at least one liquid sample | Pending | 28-Apr-2025 | ||
| WO-2026224400-A1 | Urine workflows | Pending | 25-Apr-2025 | ||
| EP-4768122-A1 | Microfluidic device for handling a fluid sample | Pending | 27-Dec-2024 | ||
| EP-4768123-A1 | Microfluidic device for handling a fluid sample | Pending | 27-Dec-2024 | B01L3/502723 |
Qiagen Signals
Qiagen Investments & Acquisitions (62)
Qiagen’s most recent deal was a Merger/Acquisition with Parse Biosciences for . The deal was made on 01-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Parse Biosciences | 01-Dec-2025 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Genoox | 23-May-2025 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
| Verogen | 03-Jan-2023 | Merger/Acquisition | Business/Productivity Software | ||
| Blirt | 11-May-2022 | Merger/Acquisition | Biotechnology | ||
| Glyphic Biotechnologies | 19-Jan-2022 | Grant | Biotechnology |
Qiagen ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
13.05 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Qiagen Exits (16)
Qiagen’s most recent exit was on 07-Jan-2019 from Ellume. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ellume | 07-Jan-2019 | Completed |
|
||
| ArcherDX | 20-Mar-2018 | Completed |
|
||
| Exosome Diagnostics | 07-Jan-2016 | Completed |
|
||
| Biotype Innovation | 04-Sep-2015 | Completed |
|
||
| AdnaGen | 17-Mar-2015 | Merger/Acquisition | Completed |
Qiagen Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Qiagen Monheim | Monheim am Rhein, Germany | 2019 | |
| Parse Biosciences | Seattle, WA | 2018 | |
| Verogen | San Diego, CA | 2017 | |
| Genoox | Palo Alto, CA | 2014 | |
| Biobase (Healthcare Services) | Wolfenbuettel, Germany | 1997 |
Qiagen FAQs
-
When was Qiagen founded?
Qiagen was founded in 1984.
-
Where is Qiagen headquartered?
Qiagen is headquartered in Hilden, Germany.
-
What is the size of Qiagen?
Qiagen has 5,700 total employees.
-
What industry is Qiagen in?
Qiagen’s primary industry is Biotechnology.
-
Is Qiagen a private or public company?
Qiagen is a Public company.
-
What is Qiagen’s stock symbol?
The ticker symbol for Qiagen is QGEN.
-
What is the current stock price of Qiagen?
As of 19-Nov-2026 the stock price of Qiagen is $49.63.
-
What is the current market cap of Qiagen?
The current market capitalization of Qiagen is $10.2B.
-
What is Qiagen’s current revenue?
The trailing twelve month revenue for Qiagen is $2.12B.
-
Who are Qiagen’s competitors?
Standard BioTools, HTG Molecular Diagnostics, Abcam, Oxford Nanopore Technologies, and Illumina are some of the 13 competitors of Qiagen.
-
What is Qiagen’s annual earnings per share (EPS)?
Qiagen’s EPS for 12 months was $1.87.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process